Objective: Generalized anxiety disorder (GAD) is a chronic anxiety disorder that leads to significant functional impairment and reduced quality of life. Pregabalin is a novel analogue of the inhibitory neurotransmitter gamma amino butyric acid, which has been proposed as a treatment for a range of conditions including GAD. This study examined the efficacy of pregabalin for GAD across published trials, using a meta-analytic method.
against excessive optimism. The results for the effect of pregabalin on HARS scores in GAD were based on only 2 RCTs, 19, 20 with each of these running for only 4 weeks. A further weakness of this meta-analysis is that the authors presented only the effect sizes from the total score of the HARS, and did not examine the effect of pregabalin on psychic anxiety and somatic anxiety factors.
My study extends on the previous meta-analysis 27 into the efficacy of pregabalin on GAD symptoms in 2 important ways. It incorporates the 5 additional trials of pregabalin that have been published that were not included in the earlier analysis. Further, it examines the effect of pregabalin on total HARS scores, as well as psychic anxiety and somatic anxiety subscales.
Method

Search Strategy and Inclusion Criteria
The psychiatric literature on the treatment of GAD with pregabalin was searched using the PubMed database of published research. The search was conducted in December 2010, using the search term pregabalin and GAD or anxiety. Articles were examined for relevance, and the references sections of each article were examined for further published trials. To meet inclusion criteria for the current metaanalysis, articles needed to be published in a peer-reviewed journal, and to describe a randomized, placebo-controlled trial of pregabalin used in the treatment of primary GAD. All included studies were of adults with GAD. For inclusion in the meta-analysis, each study was required to use the HARS as the primary outcome measure, and to provide enough published statistics to allow for the calculation of effect size measures. Studies included in the analysis are presented in Table 1 . One further unpublished study into the efficacy of pregabalin in the treatment of GAD was also identified, but was not available for the current analysis.
Statistical Analysis
The primary measure of effect size used in the metaanalysis was Hedges' g. 29 For the purpose of comparison with the earlier meta-analysis of Hidalgo et a1, 27 Cohen's d was also calculated for each study. 30 Effect sizes were calculated using the baseline and change scores provided by the original authors. Where standard errors were provided, these were converted into standard deviations. All effect sizes calculated were based on the effect of pregabalin compared against a placebo control. Correlations between pretreatment and posttreatment scores on the HARS were not available in the published results, and so an estimate of 0.96 was used, based on the 1-week test-retest reliability data published previously. 31 Where individual studies used a range of different doses of pregabalin, only the highest dose was used in the analysis to reduce the potentially confounding effect of suboptimal dosing. The use of only the highest dose for each trial also allowed for direct comparison with the earlier meta-analysis, which used the same procedure. 27 As a single outcome variable was Pregabalin is a novel analogue of the inhibitory neurotransmitter GABA, 10 which has been used to treat GAD in a series of RCTs (Table 1) . 11 Pregabalin does not interact with GABA receptors and does not alter GABA metabolism or reuptake. 12 Pregabalin is thought to exert its effect through modulation of presynaptic voltage-dependent calcium channels. Influx of calcium ions through these channels reduces exocytosis and the release of excitatory neurotransmitters into the synaptic cleft. [13] [14] [15] [16] After administration, pregabalin reaches peak serum concentrations after 0.7 to 1.5 hours. Bioavailability of oral pregabalin exceeds F = 0.90. 17 Pregabalin does not undergo extensive metabolism in the body, with about 92% excreted unchanged in urine. 18 Pregabalin does not inhibit or potentiate CYP enzyme activity, and its metabolism is not itself CYP-dependent. 10 No active metabolites are produced by the small proportion of pregabalin that is metabolized. 10 The half-life of pregabalin from a single dose is between 4.6 and 6.8 hours. 18 A total of 7 published RCTs [19] [20] [21] [22] [23] [24] [25] have investigated the efficacy of pregabalin in the treatment of adult GAD. One of these RCTs specifically examined the efficacy of pregabalin in GAD in older adults. 24 A single further study 26 has evaluated the efficacy of pregabalin in reducing the risk of relapse after successful treatment. In all previous studies, results have indicated that pregabalin has been an efficacious treatment for GAD, reducing symptoms in patients, compared with placebo control subjects, and at least as effective and other active comparator drugs, such as lorazepam, alprazolam, and venlafaxine.
Despite the existence of 8 published studies into the efficacy of pregabalin in the treatment, there has only been one previous study 27 that has conducted a meta-analysis of previous use of pregabalin for GAD. In this single metaanalysis, a range of pharmacotherapies for GAD were examined, including pregabalin. Results of this metaanalysis suggested that pregabalin had a moderate effect size (Cohen's d = 0.5) in reducing anxiety symptoms as measured by the HARS. 28 As shown in Figure 1 , placebo-controlled effect sizes ranged from 0.237 to 0.551. The overall placebo-controlled effect size across the 7 studies was 0.364 (95% CI 0.256 to 0.471, Z = 6.606, P < 0.001).
Effect Size for HARS Subscales
For each of the somatic anxiety and psychic anxiety subscales of the HARS, a total of 4 studies presented sufficient results to compute effects sizes and be used in the current meta-analysis. Together these 4 studies contained 497 people undergoing pregabalin treatment, and 416 people assigned to the pill placebo.
For the psychic anxiety subscale, the overall placebocontrolled effect sizes ranged from 0.270 to 0.436. The overall effect size across the 4 studies was significant (Hedges' g = 0.349, 95% CI 0.256 to 0.471, Z = 5.173, P < 0.001) indicating an advantage of pregabalin over placebo in the reduction of HARS psychic anxiety symptoms ( Figure 2 ). For somatic anxiety symptoms, placebo-controlled effect sizes ranged from a low of 0.194 to 0.341. Across the 4 studies, this yielded a combined effect size of Hedges' g = 0.239 (95% CI 0.107 to 0.370, Z = 3.557, P < 0.001), again indicating a significant advantage of pregabalin over placebo ( Figure 2 ).
Publication Bias
A fail-safe n calculation, using the effect size for HARS total scores, demonstrated that about 77 new or unpublished studies with negative findings would be required to reverse the present results. Figure 3 shows a funnel plot of effect size against standard error. The apparent bias in this funnel used for all effect sizes, fixed effects models were used for all meta-analyses. Meta-analyses were conducted with Comprehensive Meta-Analysis Version 2.2.057. 32 A fail-safe n analysis was conducted to examine how many studies with negative findings would be required to reverse the results of the current meta-analysis. Homogeneity of the samples from the research used in the current analysis was assessed using the Q statistic.
Results
Baseline Values
The effect of group assignment at the baseline pretreatment time point was examined to assess whether there was bias in group assignment that may confound the analysis of change scores on the HARS. Only 6 of the 7 studies analyzed presented baseline HARS data, all of which were used in the assessment of baseline equivalence. Groups assignment was not significant (mean Hedges' g = 0.087, 95% CI -0.203 to 0.378), demonstrating that the end point scores were unlikely to be confounded by differences in the pregabalin and placebo groups at the baseline assessment.
Sample Homogeneity
Homogeneity of the 7 studies included in the meta-analysis was conducted using the Q statistic. The value of the Q statistic in the current analysis was 3.795 (df = 6, P = 0.70, I 2 < 0.001), indicating that the sample was homogenous, and that a fixed effects model was appropriate.
Effect Size for HARS Total Score
A total of 7 studies were available for the meta-analysis of the effect of pregabalin on the total score from the HARS ( Table 1 ). Using only people in each study who were in the treatment groups receiving the highest dose of pregabalin, 20 Feltner et al 19 Rickels et al 21 Pohl et al 22 Montgomery et al 23 Montgomery et al 24 Kasper et al 
Discussion
My meta-analysis sought to extend on the only previous meta-analysis of the efficacy of pregabalin in the treatment of GAD. It expanded on this previous research by increasing the number of studies from 2 to 7, and also by examining the effect of pregabalin on somatic and psychic anxiety symptoms separately.
The meta-analysis of pregabalin in the treatment of GAD provides further evidence that pregabalin is an effective pharmacological treatment option. Across all 7 studies included in the meta-analysis, a small-to-moderate placebocontrolled effect size of 0.364 demonstrated that not only was pregabalin associated with a drop in anxiety symptoms but also that this was beyond that seen when given placebo. Further, the significant treatment effect for pregabalin in GAD seen in the 7 studies used in my meta-analysis are unlikely to be reversed by unpublished (or yet to be published) negative findings.
There were substantial differences in the placebo-controlled effect sizes observed for somatic and psychic anxiety symptoms as measured by the HARS subscales. The results of the analysis presented here suggest that pregabalin may be substantially better able to reduce psychic anxiety symptoms than somatic anxiety symptoms. Such a therapeutic profile more closely resembles that seen with antidepressants than with benzodiazepines. The reasons for plot would be expected to shift the mean effect size to 0.325 (95% CI 0.226 to 0.424) according to Duval and Tweedie's trim and fit calculation.
Correlation Between Placebo and Pregabalin Response
The correlation between the change associated with pregabalin in each RCT was compared with that obtained by the placebo group. Bivariate correlation between the change scores was statistically significant (r = 0.952, P = 0.001) indicating that differences in placebo response across the trials accounted for 91% of the variance in pregabalin response.
Comparison With Other Pharmacotherapies
A previous meta-analysis by Hidalgo et a1 27 reported the placebo-controlled effect sizes of a range of pharmacological interventions for GAD. The results of my study are contrasted with the results from Hidalgo et al 27 in Figure 4 . As can be seen, the results of my study, which incorporate 7 RCTs of pregabalin for GAD, yield a lower effect size estimate than the earlier work in which only the first 2 published trials were examined. In the current metaanalysis of 7 RCTs, the effect size of pregabalin is closest to that of the SSRIs in the earlier Hidalgo et al 27 meta-analysis. 
Standard error
Standard difference, mean this differential response to pregabalin on different anxiety symptoms remain unclear.
Another noteworthy observation in the current results is the large effect of a placebo in the treatment of GAD. Although treatment with pregabalin was associated with a reduction in HARS total score of between 11.8 and 14.5 points, a placebo also led to a reduction of 8.4 to 11.7 points. Further, trials in which patients experienced the largest response to pregabalin were also the same trials in which patients in the placebo group showed the largest symptom reduction. Large placebo responses to medication for psychiatric disorders have been reported in previous meta-analyses, 33, 34 although these findings have also been subjected to a critical response in subsequent literature. 35, 36 Despite this controversy, the results presented here support the idea that researchers and clinicians interpreting the efficacy of pregabalin in the treatment of GAD must remain cognizant of the large placebo response observed across all previous RCTs.
Comparison With Previous Findings
My study found an effect size that was less than that published by Hidalgo et a1 27 in their earlier work. This earlier research reported an effect size of 0.50 for pregabalin, suggesting that it may be superior to other pharmacological treatment options for GAD. This earlier effect size was based on a meta-analysis involving only the first 2 RCTs. 19, 20 In Figure 1 , none of the additional 5 RCTs published since have demonstrated effects as large as those from these first 2 studies. Larger samples used in these later studies have resulted in a substantially reduced estimate of the efficacy of pregabalin in GAD, suggesting that these earlier results may have led to an overestimate of the efficacy and effectiveness of the drug.
The current meta-analysis of 7 placebo-controlled RCTs also allows for an up-to-date comparison of pregabalin with other pharmacotherapies for GAD. While the earlier meta-analysis suggested that pregabalin may have been superior to other pharmacotherapy for GAD, the current results suggest that it is broadly comparable with other agents such as the SSRIs. Despite this, there may be a range of situations in which pregabalin presents distinct advantages, such as in combination therapies, or where other comorbid conditions, such as epilepsy or postherpetic neuralgia, are also present.
Nonpharmacological treatment options for GAD have also been investigated. The most widely investigated psychological intervention for GAD is CBT. A metaanalysis of the efficacy of CBT in the treatment of GAD has reported a placebo-controlled effect size (Hedges' g) of 0.57 on anxiety symptoms. 37 Although this is greater than that reported here for pregabalin, or for any pharmacotherapy in the earlier Hidalgo et a1 27 meta-analysis, drawing firm conclusions about the comparative efficacy of different approaches should be done cautiously. Methodological differences of included studies and differences in meta-analytic methods make firm conclusions about the comparability of different treatments difficult. Further, there are a range of other considerations, such as comorbid conditions, treatment availability, and treatment cost-effectiveness, that need to be considered in individual treatment decisions. 
Limitations and Future Directions
Although these findings provide a useful and timely synthesis of previous RCTs, the reader should be mindful of the limitations of the study. First, the meta-analysis used only the treatment groups who were taking the largest dose of pregabalin, and excluded people who were taking lower doses. Higher doses of pregabalin were, however, associated with larger treatment responses in the previous literature. As such, the results of the analysis are unlikely to provide an estimate of the efficacy of pregabalin under suboptimal dosing regimens, instead providing an indication of the effect of pregabalin at optimal or close to optimal levels. Second, the current meta-analysis combined people taking a range of different dosages of pregabalin. Most studies involved people taking a fixed dosage of 600 mg per day, [19] [20] [21] 23 or variable dosing of up to 600 mg per day, 24, 25 but one investigation used a maximum dosage of 450 mg per day. 22 Although homogeneity was established, the reader should be mindful of the potential problems with the combination of these different dosages. Third, the results presented here are based on trials of pregabalin of between 4 and 8 weeks in duration. There is currently insufficient data on the use of the drug in GAD for longer than these brief treatment trials. Only 1 published trial exists that reports on treatment for longer than 8 weeks, but this trial did not report sufficient information for inclusion in the analysis. 26 In their study, Feltner et al 26 reported on a cohort of 624 outpatients with GAD who were treated with pregabalin. Among those who entered into the study, 338 were classified as responders after 8 weeks of pregabalin treatment, and then entered into a double-blind relapse prevention phase in which participants received either pregbalin or a placebo. During the following 24 weeks, people taking pregabalin were significantly less likely to relapse, and also took longer to relapse, compared with the placebo group. Although only a single study, this provides initial, preliminary support for the use of pregabalin over longer periods.
A further set of limitations of the existing literature on pregabalin treatment of GAD concerns the funding of previous research studies, the affiliations of the researchers, and the research to date having been conducted by a limited number of researchers. All of the 7 published RCTs included in this analysis, as well as the relapse-prevention study conducted by Feltner et al, 26 received funding support from Pfizer or one of its subsidiaries. In each trial, several authors also had affiliations or positions with Pfizer. Further, many of the RCTs reviewed here share authors, meaning that the existing research into pregabalin for GAD has been conducted by a small group of people, rather than several independent research groups. Readers of the literature in this area, and the current meta-analysis, should be mindful of these limitations in the pregabalin research base.
Future research into the use of pregabalin in GAD may yield information that will assist in the understanding and treatment of the condition. The current analysis provides no information about predictors of treatment response, such as characteristics and symptoms that may be related to greater response to pregabalin treatment of GAD. Further, the current results do not provide information about the longerterm treatment effects beyond 8 weeks. Further research is needed to establish whether additional treatment effect is seen beyond 8 weeks. Additional research into optimal dosages for use of pregabalin in the treatment of GAD may also prove beneficial.
Conclusion
Pregabalin is an effective treatment for GAD, based on a series of 7 individual RCTs and a meta-analysis. Despite showing a significant advantage over placebo, the effect sizes demonstrated to date are small to moderate. There may also be different levels of symptom reduction, depending on the type of GAD symptoms examined, with psychic symptoms showing a greater reduction than somatic anxiety symptoms.
Résumé : Une méta-analyse de l'efficacité de la prégabaline dans le traitement du trouble d'anxiété généralisée Objectif : Le trouble d'anxiété généralisée (TAG) est un trouble anxieux chronique qui entraîne une incapacité fonctionnelle significative et une qualité de vie réduite. La prégabaline est un nouvel analogue de l'acide gamma-aminobutyrique, un neurotransmetteur inhibiteur, qui a été proposée comme traitement d'une série d'affections, dont le TAG. Cette étude a examiné l'efficacité de la prégabaline pour le TAG dans les essais publiés, à l'aide d'une méthode méta-analytique.
Méthode : Cette étude a examiné les 7 essais contrôlés par placebo publiés sur l'utilisation de la prégabaline pour le TAG, et, grâce à des techniques méta-analytiques, nous avons calculé l'ampleur de l'effet du traitement à la prégabaline (comparé au placebo) sur un total de 1352 personnes.
Résultats : L'ampleur de l'effet globale de la prégabaline dans le traitement du TAG était un facteur g de Hedges = 0,364, avec une ampleur de l'effet de 0,349 aux symptômes d'anxiété psychique et de 0,239 aux symptômes d'anxiété somatique.
Conclusion :
La prégabaline est une thérapie efficace pour le TAG, bien que les ampleurs de l'effet soient plus petites que celles des études précédentes. Les limitations et les orientations souhaitables de la recherche sont discutées.
